FDA 483 - Unilab Chemicals and Pharmaceuticals Pvt. Ltd. - November 22, 2019

During an inspection conducted from March 26 to April 8, 2024, the U.S. Food and Drug Administration (FDA) issued a Form FDA 483 to Triton Labs, a drug manufacturer located in Arlington, TX. The observations highlight significant deviations from current good manufacturing practices.

Key issues identified include the repeated failure to perform essential finished product testing for identity and strength of active pharmaceutical ingredients, affecting products like Triton Nasal Cleanser and Triton Ear Wax Relief. Triton Labs also failed to test incoming raw materials, including active ingredients such as sodium chloride and carbamide peroxide, for purity, strength, and quality. A further repeat observation noted the absence of a written stability testing program to assess drug product characteristics.

Additionally, the inspection revealed inadequate controls for preventing microbiological contamination in sterile drug products, specifically Triton Nasal Cleanser, which is manufactured in an uncontrolled environment without environmental monitoring or process validation. The firm also lacked critical written procedures for numerous manufacturing operations, including process validation, equipment cleaning, material handling, and batch production records. These systemic issues indicate a need for comprehensive corrective actions to ensure drug product quality, safety, and compliance with regulatory standards.